Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
Lounder DT, Khandelwal P, Chandra S, Jordan MB, Kumar AR, Grimley MS, Davies SM, Bleesing JJ, Marsh RA. Lounder DT, et al. Among authors: khandelwal p. Biol Blood Marrow Transplant. 2017 May;23(5):857-860. doi: 10.1016/j.bbmt.2017.02.011. Epub 2017 Feb 17. Biol Blood Marrow Transplant. 2017. PMID: 28219834 Free article.
Non dermatomal rash and pancytopenia in a 5 year old child.
Khandelwal P, Marsha R, Schmid DS, Folster J, Radford KW, Davies SM, Filipovich A. Khandelwal P, et al. J Clin Virol. 2014 Jun;60(2):81-3. doi: 10.1016/j.jcv.2014.03.022. Epub 2014 Apr 13. J Clin Virol. 2014. PMID: 24793965 No abstract available.
Bortezomib for refractory autoimmunity in pediatrics.
Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH. Khandelwal P, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1654-9. doi: 10.1016/j.bbmt.2014.06.032. Epub 2014 Jun 28. Biol Blood Marrow Transplant. 2014. PMID: 24979732 Free article. Clinical Trial.
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Marsh RA, et al. Among authors: khandelwal p. Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10. Biol Blood Marrow Transplant. 2015. PMID: 25865646 Free PMC article.
Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome.
Lindsley AW, Saal HM, Burrow TA, Hopkin RJ, Shchelochkov O, Khandelwal P, Xie C, Bleesing J, Filipovich L, Risma K, Assa'ad AH, Roehrs PA, Bernstein JA. Lindsley AW, et al. Among authors: khandelwal p. J Allergy Clin Immunol. 2016 Jan;137(1):179-187.e10. doi: 10.1016/j.jaci.2015.06.002. Epub 2015 Jul 17. J Allergy Clin Immunol. 2016. PMID: 26194542 Free PMC article.
438 results